Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Exclusion Criteria

• •1. Reported anamnesis for:
• •1. Intolerance or previous toxicity for hydroxychloroquine/chloroquine
• •2. Bradycardia or reduction rhythm of heart with arrythmias
• •3. Ischemic heart disease
• •4. Retinopathy
• •5. Congestive heart failure under/with use of diuretics
• •6. Favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency
• •7. Diabetes type 1
• •8. Major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy.
• •9. Severe neurological and mental illness
• •2. Any other contraindication to take hydroxychloroquine
• •3. Already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks
• •4. Use of other antiviral agents in the last 3 weeks
• •5. Subject with a positive test for SARS-CoV-2 (for Group 1)
• •6. Pregnant or lactating
• •7. Current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, Cyclosporine, Phenylbutazone, drugs that inhibit CYP2D6
• •8. Known prolonged QT syndrome or current use of drugs with known QT prolongation
• •9. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.